

## Treatment of high risk and oligo-metastatic prostate cancer

Poster Session 02

Friday, 24 March  
09:00 - 10:30

**Location:** Room Amsterdam, North Hall (Level 1)

**Chairs:** B.J. Challacombe, London (GB)  
S. Egawa, Tokyo (JP)  
R.J. Karnes, Rochester (US)

**Aims and objectives of this session**

The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 17 **Attempted nerve sparing in high risk prostate cancer: Does it have an impact on oncological and functional outcomes? A retrospective long-term single center study**  
By: [Furrer M.A.](#)<sup>1</sup>, Gross T.<sup>1</sup>, Nguyen D.P.<sup>1</sup>, Boxler S.<sup>1</sup>, Genitsch V.<sup>2</sup>, Burkhard F.<sup>1</sup>, Thalmann G.<sup>1</sup>  
**Institutes:**<sup>1</sup>University Hospital Bern, Dept. of Urology, Bern, Switzerland, <sup>2</sup>University Hospital Bern, Institute of Pathology, Bern, Switzerland
- 18 **Impact of preoperative risk on metastatic progression and cancer specific death in patients with adverse pathology at radical prostatectomy**  
By: [Boehm K.](#)<sup>1</sup>, Leyh-Bannurah S-R.<sup>2</sup>, Rosenbaum C.<sup>2</sup>, Budäus L.<sup>3</sup>, Graefen M.<sup>3</sup>, Haferkamp A.<sup>1</sup>, Tilki D.<sup>3</sup>  
**Institutes:**<sup>1</sup>University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, <sup>2</sup>University Medical Center, Dept. of Urology, Hamburg, Germany, <sup>3</sup>University Medical Center, Martini-Clinic, Hamburg, Germany
- 19 **Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients**  
By: Srougi V.<sup>1</sup>, Sanchez-Salas R.<sup>1</sup>, Secin F.<sup>2</sup>, Baghdadi M.<sup>1</sup>, Nunes-Silva I.<sup>1</sup>, [Garcia-Barreras S.](#)<sup>1</sup>, Rembeyo G.<sup>1</sup>, Rozet F.<sup>1</sup>, Galiano M.<sup>1</sup>, Barret E.<sup>1</sup>, Cathelineau X.<sup>1</sup>  
**Institutes:**<sup>1</sup>Institut Montsouris, Dept. of Urology, Paris, France, <sup>2</sup>CEMIC and San Lazaro Foundation, Dept. of Urology, Buenos Aires, Argentina
- 20 **Association between type 2 diabetes and curative treatment in men with intermediate and high risk localised prostate cancer**  
By: [Crawley D.](#)<sup>1</sup>, Garmo H.<sup>1</sup>, Rudman S.<sup>2</sup>, Stattin P.<sup>3</sup>, Zethelius B.<sup>4</sup>, Holmberg L.<sup>1</sup>, Adolfsson J.<sup>4</sup>, Van Hemelrijck M.<sup>1</sup>  
**Institutes:**<sup>1</sup>King's College London, Dept. of Cancer Epidemiology, London, United Kingdom, <sup>2</sup>Guy's and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, <sup>3</sup>Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, <sup>4</sup>Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden
- 21 **Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy**  
By: [Kamoi K.](#), Okihara K., Hongo F., Naitoh Y., Iwata A., Kanazawa M., Ushijima S., Ukimura O.  
**Institutes:**Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan
- 22 **Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series**  
By: [Bianchi M.](#)<sup>1</sup>, Colicchia M.<sup>3</sup>, Gandaglia G.<sup>2</sup>, Munegato S.<sup>4</sup>, Fossati N.<sup>2</sup>, Bandini M.<sup>2</sup>, Stabile A.<sup>2</sup>,

Dell'Oglio P.<sup>2</sup>, Suardi N.<sup>2</sup>, Gontero P.<sup>4</sup>, Karnes J.<sup>3</sup>, Joniau S.<sup>5</sup>, Spahn M.<sup>6</sup>, Montorsi F.<sup>2</sup>, Briganti A.<sup>2</sup>  
**Institutes:**<sup>1</sup>Magna Graecia University, Dept. of Urology, Catanzaro, Italy, <sup>2</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>3</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>4</sup>Molinette Hospital, Dept. of Urology, Turin, Italy, <sup>5</sup>University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, <sup>6</sup>University Hospital of Bern, Dept. of Urology, Bern, Switzerland

- 23 **Oncological and functional outcomes after RP for high or very high-risk prostate cancer – European validation of the current NCCN guideline**  
**By:** Pompe R.S.<sup>1</sup>, Gild P.<sup>2</sup>, Chun F.<sup>2</sup>, Salomon G.<sup>1</sup>, Leyh-Bannurah S-R.<sup>1</sup>, Huland H.<sup>1</sup>, Graefen M.<sup>1</sup>, Karakiewicz P.<sup>3</sup>, Tilki D.<sup>1</sup>  
**Institutes:**<sup>1</sup>Universitätsklinikum Hamburg-Eppendorf, Martini Clinic and Dept. of Urology, Hamburg, Germany, <sup>2</sup>Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, <sup>3</sup>University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada
- 24 **Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancer**  
**By:** Servián Vives P., Patel A., Winkler M.  
**Institutes:**Imperial College Nhs Trust, Dept. of Urology, London, United Kingdom
- 25 **Survival associated with radical prostatectomy versus radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis**  
**By:** Jindal T., Dalela D., Karabon P., Vetterlein M., Seisen T., Sood A., Trinh Q-D., Jeong W., Menon M., Abdollah F.  
**Institutes:**Henry Ford Hospital, Dept. of Urology, Detroit, United States of America
- 26 **Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy**  
**By:** Tennstedt P.<sup>1</sup>, Adam M.<sup>2</sup>, Tilki D.<sup>1</sup>, Steuber T.<sup>1</sup>, Haese A.<sup>1</sup>, Salomon G.<sup>1</sup>, Petersen C.<sup>3</sup>, Huland H.<sup>1</sup>, Graefen M.<sup>1</sup>, Huber W.<sup>4</sup>, Schlomm T.<sup>1</sup>  
**Institutes:**<sup>1</sup>University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, <sup>2</sup>University of Tübingen, Dept. of Urology, Tübingen, Germany, <sup>3</sup>University Medical Center Eppendorf, Dept. of Radiooncology, Hamburg, Germany, <sup>4</sup>European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Hamburg, Germany
- 27 **Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases**  
**By:** Roscigno M.<sup>1</sup>, Nicolai M.<sup>1</sup>, Naspro R.<sup>1</sup>, Pellucchi F.<sup>1</sup>, Cornaghi L.B.<sup>1</sup>, Angiolilli D.<sup>1</sup>, Chinaglia D.<sup>2</sup>, Da Pozzo L.F.<sup>1</sup>  
**Institutes:**<sup>1</sup>ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, <sup>2</sup>ASST Papa Giovanni XXIII, Dept. of Pathology, Bergamo, Italy
- 28 **Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis**  
**By:** Bianchi M.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Fossati N.<sup>1</sup>, Dell'Oglio P.<sup>1</sup>, Joniau S.<sup>2</sup>, Colicchia M.<sup>3</sup>, Munegato S.<sup>4</sup>, Bandini M.<sup>5</sup>, Spahn M.<sup>6</sup>, Scattoni V.<sup>5</sup>, Gontero P.<sup>4</sup>, Karnes J.<sup>3</sup>, Montorsi F.<sup>5</sup>, Briganti A.<sup>5</sup>  
**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele; Magna Graecia University, Dept. of Urology, Milan, Italy, <sup>2</sup>University Hospital of Leuven, Dept. of Urology, Leuven, Belgium, <sup>3</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>4</sup>University of Turin, Dept. of Urology, Turin, Italy, <sup>5</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>6</sup>University Hospital of Bern, Dept. of Urology, Bern, Switzerland
- 29 **Cytoreductive radical prostatectomy (cRP) is feasible in men with hormone-naive, metastatic prostate cancer (mPCA)**  
**By:** Heidenreich A.<sup>1</sup>, Briganti A.<sup>2</sup>, Karnes J.<sup>3</sup>, Fossati N.<sup>2</sup>, Gandaglia G.<sup>2</sup>, Montorsi F.<sup>2</sup>, Suardi N.<sup>2</sup>, Colicchia M.<sup>3</sup>, Shariat S.<sup>4</sup>, Pfister D.<sup>1</sup>  
**Institutes:**<sup>1</sup>Uniklinik Köln, Dept. of Urology, Cologne, Germany, <sup>2</sup>Vita Salute San Raffaele University, Urological Research Institute, Milan, Italy, <sup>3</sup>Mayo Clinic, Dept. of Urology, Rochester, United States

of America, <sup>4</sup>Universitätsklinik Wien, Dept. of Urology, Vienna, Austria

30

**Robot assisted radical prostatectomy in patients with oligometastatic prostate cancer**

**By:** Jang W.S.<sup>1</sup>, Heo J.E.<sup>1</sup>, Oh K.T.<sup>1</sup>, Kim M.S.<sup>1</sup>, Kang D.H.<sup>1</sup>, Jeong W.S.<sup>1</sup>, Ham W.S.<sup>1</sup>, Kim Y.S.<sup>2</sup>, Cho J.R.<sup>3</sup>, Choi Y.D.<sup>1</sup>

**Institutes:**<sup>1</sup>Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, <sup>2</sup>National Health Insurance Corporation Ilsan Hospital, Dept. of Urology and Urological Science Institute, Goyang, South Korea, <sup>3</sup>Inje University College of Medicine, Dept. of Urology and Urological Science Institute, Gimhae, South Korea

31

**Observation of preliminary clinical effect and analysis of perioperative complications of radical prostatectomy for patients with oligo-metastatic prostate cancer**

**By:** Li G., Dai B., Ye D.

**Institutes:**Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China